Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Odyssey Therapeutics, Inc.ODTX · Entity 4850 | Director | May 07, 2026 | May 12, 2026 |
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | Director | May 29, 2018 | May 30, 2018 |
| Revolution Healthcare Acquisition Corp.REVH · Entity 135631 | Director | March 17, 2021 | March 17, 2021 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director · Executive Chairman | February 24, 2026 | February 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Odyssey Therapeutics, Inc.
Report date May 07, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 270,198 |
Reported balance
After 2026-05-08 transaction · row 1
1 source rowRow 1 · 2026-05-08 · Purchase · Acquired 5,000 · Balance 270,198 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 31,644 |
Last balance in matching sequence
After 2026-05-11 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 2 · 2026-05-11 · Conversion · Acquired 28,698 · Balance 28,698 F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. Row 3 · 2026-05-11 · Exercise / conversion · Acquired 2,963 · Balance 31,661 F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. Row 4 · 2026-05-11 · Tax withholding · Disposed 17 · Balance 31,644 F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F6: Pursuant to the terms of the warrants, the Issuer withheld 17 warrant shares to pay the exercise price in connection with the net exercise. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-11 · Conversion · Disposed 79,166 · Balance 0 F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-11 · Conversion · Disposed 100,000 · Balance 0 F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Series D Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-11 · Conversion · Disposed 96,002 · Balance 0 F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06 | Direct | 626,220 |
Reported balance
After 2026-05-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-07 · Grant · Acquired 626,220 · Balance 626,220 F8: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date. |
| Series D Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.10 | IndirectSee footnote | 0 |
Reported balance
After 2026-05-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-11 · Exercise / conversion · Disposed 28,800 · Balance 0 F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration.
F2: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
F3: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.
F4: These securities are held of record by Racing Beach Ventures LLC ("Racing Beach"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities.
F5: The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis.
F6: Pursuant to the terms of the warrants, the Issuer withheld 17 warrant shares to pay the exercise price in connection with the net exercise.
F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.
F8: Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date.
QUEST DIAGNOSTICS INC
Report date May 29, 2018 · Filed May 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,000 |
Reported balance
After 2018-05-29 transaction · row 1
1 source rowRow 1 · 2018-05-29 · Sale · Disposed 1,644 · Balance 6,000 |
Revolution Healthcare Acquisition Corp.
Report date March 17, 2021 · Filed March 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B common stockSEC Table I · non-derivative | IndirectBy Racing Beach Ventures LLC | 7,500 |
Reported balance
Holding disclosure · report date 2021-03-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 7,500 F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-253729), as amended, under the heading "Description of Securities - Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the Issuer after the consummation of the Issuer's initial business combination. F2: Shares held directly by Racing Beach Ventures LLC. The Reporting Person is a managing member of Racing Beach Ventures LLC and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the Issuer's registration statement on Form S-1 (File No. 333-253729), as amended, under the heading "Description of Securities - Alignment Shares", the shares of Class B common stock, par value $0.0001, will convert into shares of Class A common stock, par value $0.0001, pursuant to the performance of publicly traded shares of Class A common stock of the Issuer after the consummation of the Issuer's initial business combination.
F2: Shares held directly by Racing Beach Ventures LLC. The Reporting Person is a managing member of Racing Beach Ventures LLC and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
VERTEX PHARMACEUTICALS INC / MA
Report date February 24, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,797 |
Reported balance
After 2026-02-24 transaction · row 1
1 source rowRow 1 · 2026-02-24 · Tax withholding · Disposed 3,547 · Balance 34,797 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 440 |
Reported balance
Holding disclosure · report date 2026-02-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 440 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABBOTT LABORATORIES
Report date March 24, 2006 · Filed March 28, 2006
Section 16 reporting ended · disclosed 2006-03-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 209,401 |
Ending reported balance
After 2006-03-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2006-03-24 · Tax withholding · Disposed 91,846 · Balance 309,401 Row 2 · 2006-03-24 · Disposition to issuer · Disposed 100,000 · Balance 209,401 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 635 |
Reported balance
Holding disclosure · report date 2006-03-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 635 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of March 24, 2006. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of March 24, 2006.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 17, 2004 Filed Feb 18, 2004 23:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 13,444 | $0.00 Strike: $35.36 | $0.00 |
DisclosureSEC source: 0001104659-04-005014 · a4.xml · derivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 436,556 Underlying: common shares · 13,444 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2004 Filed Feb 18, 2004 23:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 11,800 | $44.31 | $522,858.00 |
DisclosureSEC source: 0001104659-04-005014 · a4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,992 Read SEC document |
| February 17, 2004 Filed Feb 18, 2004 23:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 13,444 | $35.36 | $475,379.84 |
DisclosureSEC source: 0001104659-04-005014 · a4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · President & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.